Twist Biosciences Presents: Validating AI-Designed Therapeutics at Scale

​Join us for a private, lunch-time conversation at MBC BioLabs exploring how AI-designed proteins and antibodies are moving from in-silico design to real-world validation. This session will kick off with a fireside chat featuring Twist Bioscience’s Chief Scientific Officer, followed by a panel discussion with leaders across therapeutics, RNA research, and screening platforms.

​Together, the group will discuss how AI-driven molecules are being validated at scale, where current industry bottlenecks remain, emerging technical and operational solutions, and what’s next for AI-enabled therapeutic discovery.

​Agenda highlights include:

• ​Fireside chat with Twist Bioscience CSO

• ​Panel discussion on scaling validation for AI-designed biologics

• ​Open discussion on challenges, solutions, and future directions

​Panelists:

• ​Colby Souders, PhD – Chief Scientific Officer, Twist Bioscience

• ​Timo Hagen – Director of RNA Research, Therna

• ​Sharrol Bachas – Chief Scientific Officer & Co-Founder, Onava

• ​David Yuan – Head of Screening Platform, Latent Labs

• ​Nikhil Haas – CEO & Co-Founder, BioLM

​🍽️ Lunch will be provided.